Fresenius to fight adverse merger decision:
This article was originally published in Clinica
Executive Summary
Fresenius (Germany) has vowed to challenge a decision taken this month by the cartel office barring its merger with Schiwa (see Clinica No 601, p 13). The court maintains that the merger would lead to a dominant position in the German infusion and dialysis products market. Fresenius, however, stresses the importance of strengthening its presence in the European market.